在HER2-阳性转移性乳腺癌中对阿多-特拉斯图苏巴姆 (Ado-Trastuzumab) 埃姆坦辛的异常和持久的完整反应:一个病例报告
Yuko Tashima1, Yurie Araki1, Shinichi Araki1
1Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, JPN.
Cureus
|March 4, 2026
概括
艾多-特拉斯图祖马布埃姆坦辛 (T-DM1) 在HER2阳性转移性乳腺癌中提供了罕见的,持久的完全缓解. 本案例研究显示,持续响应超过五年,突出T-DM1.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床案例研究 临床案例研究
背景情况:
- 艾多-特拉斯图祖马布埃姆坦辛 (T-DM1) 是对 HER2 阳性转移性乳腺癌的标准治疗方法,用于特拉斯图祖马布治疗后的治疗.
- 对T-DM1的完整和持久的反应很少发生,很少有长期缓解的报道.
研究的目的:
- 报告 HER2 阳性转移性乳腺癌患者对 T-DM1 持续完全反应的特殊病例.
- 突出持久缓解的潜力,并探索影响T-DM1.1异常反应的因素.
主要方法:
- 一名72岁妇女患有HER2阳性转移性乳腺癌的病例报告.
- 患者接受了第一线化疗,维持抗HER2疗法和手术.
- 在内分泌疗法治疗疾病进展后启动T-DM1;通过CT成像和临床监测评估反应.
主要成果:
- 患者在T-DM1启动后三个月内实现了明显的瘤回归.
- 随着持续的T-DM1治疗,完全的放射性缓解已经持续了五年多.
- 副作用仅限于轻度肝功能障碍;没有发生显著的血小板缩.
结论:
- 这种病例代表了对T-DM1的异常反应,表明在选择的HER2阳性转移性乳腺癌患者中具有持久完全缓解的潜力.
- 需要进行进一步的研究,以确定特殊反应的预测生物标志物,并优化T-DM1治疗持续时间.
关键词:
亚多-特拉斯图祖马布 (ado-trastuzumab) 是一种含有埃姆坦辛的药物.抗her2治疗的治疗方法案例报告案例报告一个完整的响应反应的完整反应.持久的反应 持久的反应一个特殊的响应者.她2阳性的转移性乳腺癌.长期生存率 长期生存率更多相关视频
11:02Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
Published on: September 14, 2018
8.6K
10:19Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells
Published on: May 12, 2023
1.7K
相关概念视频
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...